LIVIVO - Search results -

Search results

Result 1 - 10 of total 425

Search options

Article ; Online: A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation.

Hüttner, Sören S / Henze, Henriette / Elster, Dana / Koch, Philipp / Anderer, Ursula / von Eyss, Björn / von Maltzahn, Julia

Molecular therapy : the journal of the American Society of Gene Therapy

2023 Volume 31, Issue 9, Page(s) 2612–2632

Abstract: Rhabdomyosarcoma is the most common pediatric soft tissue tumor, comprising two major subtypes: the PAX3/7-FOXO1 fusion-negative embryonal and the PAX3/7-FOXO1 fusion-positive alveolar subtype. Here, we demonstrate that the expression levels of the ... ...

Abstract	Rhabdomyosarcoma is the most common pediatric soft tissue tumor, comprising two major subtypes: the PAX3/7-FOXO1 fusion-negative embryonal and the PAX3/7-FOXO1 fusion-positive alveolar subtype. Here, we demonstrate that the expression levels of the transcriptional repressor TRPS1 are specifically enhanced in the embryonal subtype, resulting in impaired terminal myogenic differentiation and tumor growth. During normal myogenesis, expression levels of TRPS1 have to decrease to allow myogenic progression, as demonstrated by overexpression of TRPS1 in myoblasts impairing myotube formation. Consequentially, myogenic differentiation in embryonal rhabdomyosarcoma in vitro as well as in vivo can be achieved by reducing TRPS1 levels. Furthermore, we show that TRPS1 levels in RD cells, the bona fide model cell line for embryonal rhabdomyosarcoma, are regulated by miR-1 and that TRPS1 and MYOD1 share common genomic binding sites. The myogenin (MYOG) promoter is one of the critical targets of TRPS1 and MYOD1; we demonstrate that TRPS1 restricts MYOG expression and thereby inhibits terminal myogenic differentiation. Therefore, reduction of TRPS1 levels in embryonal rhabdomyosarcoma might be a therapeutic approach to drive embryonal rhabdomyosarcoma cells into myogenic differentiation, thereby generating postmitotic myotubes.
MeSH term(s)	Humans ; Child ; Rhabdomyosarcoma, Embryonal/genetics ; Rhabdomyosarcoma, Embryonal/metabolism ; Rhabdomyosarcoma, Embryonal/pathology ; Myogenin/genetics ; Myogenin/metabolism ; Cell Differentiation/genetics ; MicroRNAs/genetics ; Muscle Development/genetics ; Cell Line, Tumor ; Repressor Proteins
Chemical Substances	Myogenin ; MicroRNAs ; TRPS1 protein, human ; Repressor Proteins ; MYOG protein, human ; MIRN1 microRNA, human
Language	English
Publishing date	2023-07-14
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2010592-7
ISSN	1525-0024 ; 1525-0016
ISSN (online)	1525-0024
ISSN	1525-0016
DOI	10.1016/j.ymthe.2023.07.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5640: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Full-Length Single Protein Molecules Tracking and Counting in Thin Silicon Channels.

Ohayon, Shilo / Taib, Liran / Verma, Navneet Chandra / Iarossi, Marzia / Bhattacharya, Ivy / Marom, Barak / Huttner, Diana / Meller, Amit

Advanced materials (Deerfield Beach, Fla.)

2024 , Page(s) e2314319

Abstract: Emerging single-molecule protein sensing techniques are ushering in a transformative era in biomedical research. Nevertheless, challenges persist in realizing ultra-fast full-length protein sensing, including loss of molecular integrity due to protein ... ...

Abstract	Emerging single-molecule protein sensing techniques are ushering in a transformative era in biomedical research. Nevertheless, challenges persist in realizing ultra-fast full-length protein sensing, including loss of molecular integrity due to protein fragmentation, biases introduced by antibodies affinity, identification of proteoforms, and low throughputs. Here, a single-molecule method for parallel protein separation and tracking is introduced, yielding multi-dimensional molecular properties used for their identification. Proteins are tagged by chemo-selective dual amino-acid specific labels and are electrophoretically separated by their mass/charge in custom-designed thin silicon channel with subwavelength height. This approach allows analysis of thousands of individual proteins within a few minutes by tracking their motion during the migration. The power of the method is demonstrated by quantifying a cytokine panel for host-response discrimination between viral and bacterial infections. Moreover, it is shown that two clinically-relevant splice isoforms of Vascular endothelial growth factor (VEGF) can be accurately quantified from human serum samples. Being non-destructive and compatible with full-length intact proteins, this method opens up ways for antibody-free single-protein molecule quantification.
Language	English
Publishing date	2024-03-09
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1474949-X
ISSN	1521-4095 ; 0935-9648
ISSN (online)	1521-4095
ISSN	0935-9648
DOI	10.1002/adma.202314319
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Connaissances actuelles concernant l'utilisation des antibiotiques. L'utilisation d'antibiotiques est un facteur majeur d'émergence et de propagation des résistances bactériennes. Quelles sont les recommandations actuelles d'antibiothérapie chez les patients atteints de COVID-19?

Catho, G. / Søgaard, K. K. / Egli, A. / Hüttner, B. D.

Swiss medical forum

2020 Volume 20, Issue 47/48, Page(s) 695

Language	German
Document type	Article
ZDB-ID	2220114-2
ISSN	1661-6138
Database	Current Contents Medicine

In stock of ZB MED Cologne/Königswinter

Zs.A 5471: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Dolphin-WET-Development of a Welfare Evaluation Tool for Bottlenose Dolphins (

Baumgartner, Katrin / Hüttner, Tim / Clegg, Isabella L K / Hartmann, Manuel Garcia / Garcia-Párraga, Daniel / Manteca, Xavier / Mercera, Birgitta / Monreal-Pawlowsky, Tania / Pilenga, Cristina / Ternes, Kerstin / Tallo-Parra, Oriol / Vaicekauskaite, Ruta / Fersen, Lorenzo von / Yon, Lisa / Delfour, Fabienne

Animals : an open access journal from MDPI

2024 Volume 14, Issue 5

Abstract: Ensuring high standards of animal welfare is not only an ethical duty for zoos and aquariums, but it is also essential to achieve their conservation, education, and research goals. While for some species, animal welfare assessment frameworks are already ... ...

Abstract	Ensuring high standards of animal welfare is not only an ethical duty for zoos and aquariums, but it is also essential to achieve their conservation, education, and research goals. While for some species, animal welfare assessment frameworks are already in place, little has been done for marine animals under human care. Responding to this demand, the welfare committee of the European Association for Aquatic Mammals (EAAM) set up a group of experts on welfare science, cetacean biology, and zoo animal medicine across Europe. Their objective was to develop a comprehensive tool to evaluate the welfare of bottlenose dolphins (
Language	English
Publishing date	2024-02-23
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2606558-7
ISSN	2076-2615
ISSN	2076-2615
DOI	10.3390/ani14050701
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Book: Gesundheitsbezogene Verwaltungslandschaft: die vernachlässigte Grundlage kommunaler Gesundheitspolitik und -förderung

Grunow, Dieter / Hüttner, Bernd

(Sozialplanung und Sozialverwaltung ; 21)

1998

Author's details	Dieter Grunow ; Bernd Hüttner
Series title	Sozialplanung und Sozialverwaltung ; 21
Collection
Keywords	München ; Stadtverwaltung ; Gesundheitspolitik ; Gesundheitsförderung
Subject	Health Promotion ; Gesundheit ; Stadt
Language	German
Size	V, 209 S.
Publisher	Kleine
Publishing place	Bielefeld
Publishing country	Germany
Document type	Book
HBZ-ID	HT009127646
ISBN	3-89370-278-4 ; 978-3-89370-278-7
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
1999 A 2964	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The changing landscape in epilepsy imaging: Unmasking subtle and unique entities.

Adin, Mehmet E / Durand, David / Zucconi, William B / Huttner, Anita J / Spencer, Dennis D / Bronen, Richard A

Diagnostic and interventional radiology (Ankara, Turkey)

2022 Volume 28, Issue 5, Page(s) 503–515

Abstract: Dramatic changes have occurred recently in the field of epilepsy, including a fundamental shift in the etiology of epileptogenic substrates found at surgery. Hippocampal sclerosis is no longer the most common etiology found at epilepsy surgery and this ... ...

Abstract	Dramatic changes have occurred recently in the field of epilepsy, including a fundamental shift in the etiology of epileptogenic substrates found at surgery. Hippocampal sclerosis is no longer the most common etiology found at epilepsy surgery and this decrease has been associated with an increase in the incidence of focal cortical dysplasia and encephaloceles. Significant advances have been made in molecular biology and genetics underlying the basis of malformations of cortical development, and our ability to detect epileptogenic abnormalities with MR imaging has markedly improved. This article begins with a discussion of these trends and reviews imaging techniques essential for detecting of subtle epilepsy findings. Representative examples of subtle imaging findings are presented, which are often overlooked but should not be missed. These include temporal lobe encephaloceles, malformations of cortical development (and especially focal cortical dysplasia), hippocampal sclerosis, hippocampal malformation (also known as HIMAL), ulegyria, autoimmune encephalitis, and Rasmussen's encephalitis. Recent findings on the pathophysiology and genetic underpinnings of several causes of localization-related epilepsy are incorporated. For instance, it has been recently found that focal cortical dysplasia IIb, tuberous sclerosis, hemimegalencephaly, and gangliogliomas are all the result of mutations of the mTOR pathway for cell growth.
MeSH term(s)	Atrophy ; Encephalitis/complications ; Encephalocele/complications ; Epilepsy/diagnostic imaging ; Epilepsy/genetics ; Humans ; Malformations of Cortical Development/complications ; Malformations of Cortical Development/diagnostic imaging ; Malformations of Cortical Development/genetics ; Sclerosis/complications ; TOR Serine-Threonine Kinases/metabolism
Chemical Substances	TOR Serine-Threonine Kinases (EC 2.7.11.1)
Language	English
Publishing date	2022-08-23
Publishing country	Turkey
Document type	Journal Article
ZDB-ID	2184145-7
ISSN	1305-3612 ; 1305-3612
ISSN (online)	1305-3612
ISSN	1305-3612
DOI	10.5152/dir.2022.21339
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Assessing the Appropriateness of Formulations on the WHO Model List of Essential Medicines for Children: Development of a Paediatric Quality Target Product Profile Tool.

Walsh, Jennifer / Masini, Tiziana / Huttner, Benedikt D / Moja, Lorenzo / Penazzato, Martina / Cappello, Bernadette

Pharmaceutics

2022 Volume 14, Issue 3

Abstract: The World Health Organization's Model List of Essential Medicines for Children (EMLc) presents a list of the most efficacious, safe, and cost-effective medicines for priority conditions, intended for use in children up to 12 years of age. However, gaps ... ...

Abstract	The World Health Organization's Model List of Essential Medicines for Children (EMLc) presents a list of the most efficacious, safe, and cost-effective medicines for priority conditions, intended for use in children up to 12 years of age. However, gaps in global availability and use of age-appropriate formulations of medicines for children still exist. To address these shortcomings, a comprehensive analysis of the appropriateness of formulations of essential medicines for children is being undertaken through the Global Accelerator for Paediatric Formulations (GAP-f) network, a WHO network launched in 2020 to respond to the paediatric treatment gap. This article describes the development and application of a paediatric Quality Target Product Profile (pQTPP) tool by WHO, to retrospectively evaluate the paediatric age-appropriateness of formulations on the EMLc and identify potential formulation gaps, to inform the review of the EMLc in 2023. A combination of paediatric-centric and global health-focused attributes and targets were defined, taking into consideration regulatory agency paediatric development guidelines and literature sources, and a qualitative scoring system was developed and tested. Example evaluations of paracetamol and clofazimine are provided, illustrating the tool's use. The assessment of EMLc formulations is ongoing and shortcomings and gaps in EMLc formulations have already been identified. The pQTTP tool may also be applied to national lists and prospectively when designing new paediatric formulations.
Language	English
Publishing date	2022-02-22
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527217-2
ISSN	1999-4923
ISSN	1999-4923
DOI	10.3390/pharmaceutics14030473
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: 'A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae' - Author's reply.

Huttner, B D / Galperine, T / Kapel, N / Harbarth, S

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

2019 Volume 25, Issue 7, Page(s) 914–915

MeSH term(s)	Anti-Bacterial Agents ; Enterobacteriaceae ; Enterobacteriaceae Infections ; Fecal Microbiota Transplantation ; Humans ; beta-Lactamases
Chemical Substances	Anti-Bacterial Agents ; beta-Lactamases (EC 3.5.2.6)
Language	English
Publishing date	2019-02-13
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	1328418-6
ISSN	1469-0691 ; 1470-9465 ; 1198-743X
ISSN (online)	1469-0691
ISSN	1470-9465 ; 1198-743X
DOI	10.1016/j.cmi.2019.02.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4541: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 284: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Tackling the threat of antimicrobial resistance in neonates and children: outcomes from the first WHO-convened Paediatric Drug Optimisation exercise for antibiotics.

Bamford, Alasdair / Masini, Tiziana / Williams, Phoebe / Sharland, Mike / Gigante, Valeria / Dixit, Devika / Sati, Hatim / Huttner, Benedikt / Bin Nisar, Yasir / Cappello, Bernadette / Were, Wilson / Cohn, Jennifer / Penazzato, Martina

The Lancet. Child & adolescent health

2024

Abstract: Children and neonates are highly vulnerable to the impact of antimicrobial resistance. Substantial barriers are faced in relation to research and development of antibacterial agents for use in neonates, children, and adolescents aged yonger than 19 years, ...

Abstract	Children and neonates are highly vulnerable to the impact of antimicrobial resistance. Substantial barriers are faced in relation to research and development of antibacterial agents for use in neonates, children, and adolescents aged yonger than 19 years, and focusing finite resources on the most appropriate agents for development and paediatric optimisation is urgently needed. In November and December, 2022, following the successes of previous similar disease-focused exercises, WHO convened the first Paediatric Drug Optimisation (PADO) exercise for antibiotics, aiming to provide a shortlist of antibiotics to be prioritised for paediatric research and development, especially for use in regions with the highest burden of disease attributable to serious bacterial infection. A range of antibiotics with either existing license for children or in clinical development in adults but with little paediatric data were considered, and PADO priority and PADO watch lists were formulated. This Review provides the background and overview of the exercise processes and its outcomes as well as a concise review of the literature supporting decision making. Follow-up actions to implement the outcomes from the PADO for antibiotics process are also summarised. This Review highlights the major beneficial influence the collaborative PADO process can have, both for therapeutic drug class and disease-specific themes, in uniting efforts to ensure children have access to essential medicines across the world.
Language	English
Publishing date	2024-04-19
Publishing country	England
Document type	Journal Article ; Review
ISSN	2352-4650
ISSN (online)	2352-4650
DOI	10.1016/S2352-4642(24)00048-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Comparison of edoxaban and enoxaparin in a rat model of AlCl

Hachenberger, M / Yeniguen, M / Suenner, L / Hinchliffe, D / Mueller, C / Wietelmann, A / Gerriets, T / Tschernatsch, M / Juenemann, M / Gerner, S T / Doeppner, T R / Huttner, H B / Braun, T

Naunyn-Schmiedeberg's archives of pharmacology

2023 Volume 396, Issue 12, Page(s) 3887–3892

Abstract: Cerebral sinus venous thrombosis (CSVT) is an uncommon disease that is usually treated with anticoagulation (heparin, low-molecular heparin, or vitamin K-antagonists). We compared treatment with edoxaban, an oral factor Xa-antagonist, that has not been ... ...

Abstract	Cerebral sinus venous thrombosis (CSVT) is an uncommon disease that is usually treated with anticoagulation (heparin, low-molecular heparin, or vitamin K-antagonists). We compared treatment with edoxaban, an oral factor Xa-antagonist, that has not been approved in patients with CSVT, with enoxaparin, a well-established therapy, in a rat model of CSVT. Fifty male Wistar rats were randomized into 5 groups (10 animals each) and subjected to aluminum chloride (AlCl3)-induced thrombosis of the superior sagittal sinus (SSS) or sham procedure. Animals with thrombosis of the SSS were treated with edoxaban, enoxaparin, or placebo. Diagnostic workup included neurological examination, MRI imaging, MR-flow measurements of the SSS, and immunohistochemical staining. Neurological examination revealed no differences between treatment groups. Seven days after initial thrombosis, flow in the SSS was lower in the active treatment group as compared to sham-operated animals (p < 0.05). Flow in the SSS in the active treatment groups (edoxaban 1 h prior to thrombosis: 0.16 cm/s ± 0.06 cm/s; edoxaban 6 h after thrombosis: 0.13 cm/s ± 0.05 cm/s; enoxaparin: 0.13 cm/s ± 0.04 cm/s; placebo: 0.07 cm/s ± 0.02 cm/s) was higher as compared to placebo (p < 0.05), but there were no differences between the active treatment groups (p > 0.05). Immunohistochemical staining showed no differences in the actively treated animals. Edoxaban proved to be similar to enoxaparin in a model of experimental AlCl
MeSH term(s)	Humans ; Male ; Rats ; Animals ; Enoxaparin/pharmacology ; Enoxaparin/therapeutic use ; Superior Sagittal Sinus ; Rats, Wistar ; Factor Xa Inhibitors/pharmacology ; Factor Xa Inhibitors/therapeutic use ; Heparin/pharmacology ; Thrombosis/chemically induced ; Thrombosis/drug therapy
Chemical Substances	Enoxaparin ; edoxaban (NDU3J18APO) ; Factor Xa Inhibitors ; Heparin (9005-49-6)
Language	English
Publishing date	2023-06-01
Publishing country	Germany
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	121471-8
ISSN	1432-1912 ; 0028-1298
ISSN (online)	1432-1912
ISSN	0028-1298
DOI	10.1007/s00210-023-02546-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.5: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito